On October 23, 2026, WuXi Biologics is trading at HK$43.16, down 4.64%, amid broad pressure across Hong Kong equities. - Reuters described the latest reported session as an Asian selloff led by technology shares, linked to concerns about AI investment costs and escalating Gulf tensions; Hong Kong’s Hang Seng fell more than 3%. - No clear company-specific announcement explaining the decline surfaced in the search. The wider market backdrop is the strongest available explanation, but does not establish a company-specific catalyst.